Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis
Background. Uric acid nephropathy, also known as hyperuricemia nephropathy or gouty nephropathy, is characterized by uric acid crystal deposition and inflammatory cell infiltration. Herein, we aimed to demonstrate the role of febuxostat on uric acid levels and renal function in patients with chronic...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Applied Bionics and Biomechanics |
| Online Access: | http://dx.doi.org/10.1155/2022/9704862 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549061571379200 |
|---|---|
| author | Yanqun Zheng Jia Sun |
| author_facet | Yanqun Zheng Jia Sun |
| author_sort | Yanqun Zheng |
| collection | DOAJ |
| description | Background. Uric acid nephropathy, also known as hyperuricemia nephropathy or gouty nephropathy, is characterized by uric acid crystal deposition and inflammatory cell infiltration. Herein, we aimed to demonstrate the role of febuxostat on uric acid levels and renal function in patients with chronic kidney disease and hyperuricemia. Methods. Eight databases included were searched for clinical randomized controlled trials. Meanwhile, the confidence interval (CI) of either relative risk or mean difference was set to 95%. Besides, the heterogeneity of the research results is tested by I2. Results. Ten studies were ultimately included in this meta-analysis. All of them were considered to be random controlled trials. 10 studies reported the serum uric acid of the test group and the control group, which was significantly lower (SMD: -146.44, 95% Cl: -195.96, -86.93, and P<0.01) than the control group, EGFR (SMD: 3.21, 95% Cl: 1.17, 5.25, and P<0.01), serum creatinine (SMD: -15.27, 95% Cl: -20.75, -9.79, and P<0.01), serum urea nitrogen (SMD: -2.37, 95% Cl: -3.31, -1.61, and P<0.01), and adverse reactions (OR: 0.74, 95% Cl: 0.32, 1.68, and P=0.47). Conclusion. The results of this study suggest that febuxostat may be effective in patients with CKD with HUA, as evidenced by serum uric acid, creatinine, urea nitrogen, and EGFR. However, large sample, multicenter, low risk of bias clinical studies, as well as basic medical research, are needed. |
| format | Article |
| id | doaj-art-d4353c1ba81345f2be1e734788a6951d |
| institution | Kabale University |
| issn | 1754-2103 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Applied Bionics and Biomechanics |
| spelling | doaj-art-d4353c1ba81345f2be1e734788a6951d2025-02-03T06:12:24ZengWileyApplied Bionics and Biomechanics1754-21032022-01-01202210.1155/2022/9704862Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-AnalysisYanqun Zheng0Jia Sun1Nephrology DepartmentNephrology DepartmentBackground. Uric acid nephropathy, also known as hyperuricemia nephropathy or gouty nephropathy, is characterized by uric acid crystal deposition and inflammatory cell infiltration. Herein, we aimed to demonstrate the role of febuxostat on uric acid levels and renal function in patients with chronic kidney disease and hyperuricemia. Methods. Eight databases included were searched for clinical randomized controlled trials. Meanwhile, the confidence interval (CI) of either relative risk or mean difference was set to 95%. Besides, the heterogeneity of the research results is tested by I2. Results. Ten studies were ultimately included in this meta-analysis. All of them were considered to be random controlled trials. 10 studies reported the serum uric acid of the test group and the control group, which was significantly lower (SMD: -146.44, 95% Cl: -195.96, -86.93, and P<0.01) than the control group, EGFR (SMD: 3.21, 95% Cl: 1.17, 5.25, and P<0.01), serum creatinine (SMD: -15.27, 95% Cl: -20.75, -9.79, and P<0.01), serum urea nitrogen (SMD: -2.37, 95% Cl: -3.31, -1.61, and P<0.01), and adverse reactions (OR: 0.74, 95% Cl: 0.32, 1.68, and P=0.47). Conclusion. The results of this study suggest that febuxostat may be effective in patients with CKD with HUA, as evidenced by serum uric acid, creatinine, urea nitrogen, and EGFR. However, large sample, multicenter, low risk of bias clinical studies, as well as basic medical research, are needed.http://dx.doi.org/10.1155/2022/9704862 |
| spellingShingle | Yanqun Zheng Jia Sun Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis Applied Bionics and Biomechanics |
| title | Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis |
| title_full | Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis |
| title_fullStr | Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis |
| title_full_unstemmed | Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis |
| title_short | Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis |
| title_sort | febuxostat improves uric acid levels and renal function in patients with chronic kidney disease and hyperuricemia a meta analysis |
| url | http://dx.doi.org/10.1155/2022/9704862 |
| work_keys_str_mv | AT yanqunzheng febuxostatimprovesuricacidlevelsandrenalfunctioninpatientswithchronickidneydiseaseandhyperuricemiaametaanalysis AT jiasun febuxostatimprovesuricacidlevelsandrenalfunctioninpatientswithchronickidneydiseaseandhyperuricemiaametaanalysis |